BIAF
bioAffinity Technologies, Inc.
+3.16 (+58.98%)8.51USD12.4M成交股數68.9M市值–本益比(近四季)11.7股價營收比+19.0%營收年增(近四季)–下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 12 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | 1.5M-19% | 1.4M-39% | 1.4M-38% | 1.3M-47% | 1.9M-23% | 2.2M+640% | 2.4M+11808% | 2.4M+260231% | 2.4M | 298K | 20K | 921.00 |
| 營業成本 | – | – | – | – | – | – | – | – | – | 75K | 1K | 87.00 |
| 毛利 | – | – | – | – | – | – | – | – | – | 224K | 19K | 834.00 |
| 毛利率 | – | – | – | – | – | – | – | – | – | 75.0% | 93.7% | 90.6% |
| 研發費用 | 362K | 350K | 331K | 311K | 367K | 391K | 274K | 402K | 394K | 330K | 335K | 370K |
| 銷售管理費用 | 2.9M | 3.2M | 2.2M | 2.2M | 2.5M | 2.9M | 2.4M | 2.5M | 2.2M | 2.0M | 1.4M | 1.1M |
| 營業利益 | −3.3M+27% | −3.6M+23% | −2.3M+16% | −2.5M+20% | −2.6M+35% | −2.9M+28% | −2.0M+11% | −2.1M+34% | −1.9M | −2.3M | −1.8M | −1.6M |
| 營業利益率 | -220.8% | -267.6% | -158.6% | -198.2% | -141.7% | -133.5% | -84.0% | -87.1% | -80.8% | -768.7% | -9,009.8% | -169,160.7% |
| 稅後淨利 | −3.4M+27% | −3.6M+22% | −5.1M+152% | −4.1M+92% | −2.7M+36% | −3.0M+30% | −2.0M+15% | −2.1M+38% | −2.0M | −2.3M | −1.7M | −1.5M |
| 淨利率 | -222.8% | -268.6% | -349.3% | -319.9% | -143.5% | -134.4% | -85.1% | -88.0% | -81.5% | -767.5% | -8,816.4% | -166,426.7% |
| 稀釋 EPS | -0.64-87% | -0.81-95% | -4.74-2% | -5.07+2568% | -4.80+2300% | -17.27+6542% | -4.84+2320% | -0.19+6% | -0.20 | -0.26 | -0.20 | -0.18 |
| 稀釋股數 | 5.2M | 4.5M | 1.1M | 801K | 542K | 404K | 413K | 11.4M | 9.9M | 8.7M | 8.5M | 8.4M |
資產負債表 期末餘額
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | 2.4M | 3.1M | 7.7M | 803K | 445K | 1.1M | 757K | 801K | 2.5M | 4.5M | 8.3M | 9.8M |
| 應收帳款 | – | – | – | – | – | – | – | – | – | 1.1M | – | – |
| 存貨 | 82K | 78K | 35K | 44K | 39K | 28K | 25K | 30K | 9K | 10K | 10K | 11K |
| 總資產 | 7.6M | 7.9M | 11.5M | 4.8M | 5.5M | 6.5M | 6.6M | 6.7M | 8.0M | 10.2M | 8.9M | 10.5M |
| 有息負債 | – | – | – | – | – | – | – | – | – | – | – | – |
| 總負債 | 3.9M | 4.3M | 2.6M | 6.9M | 4.1M | 3.9M | 3.4M | 3.2M | 2.8M | 3.2M | 775K | 796K |
| 股東權益 | 3.8M | 3.6M | 8.9M | −2.1M | 1.4M | 2.6M | 3.1M | 3.4M | 5.3M | 7.0M | 8.1M | 9.7M |
| 負債比 | 50.5% | 53.9% | 22.9% | 145.0% | 74.1% | 60.1% | 52.4% | 48.4% | 34.7% | 31.4% | 8.7% | 7.6% |
| 淨現金(現金 − 有息負債) | – | – | – | – | – | – | – | – | – | – | – | – |
現金流量表 單季
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | – | −3.2M | – | – | −1.6M-30% | – | – | – | −2.3M | – | – | −1.5M |
| 資本支出 | – | 6K | – | – | 51K | – | – | – | 41K | – | – | 32K |
| 自由現金流 | – | −3.2M | – | – | −1.7M-29% | – | – | – | −2.4M | – | – | −1.6M |
| 折舊攤銷 | 62K | 115K | 113K | 113K | 155K | 154K | 151K | 151K | 150K | 58K | 22K | 22K |
| 買回庫藏股 | – | – | – | – | – | – | – | – | – | – | – | – |
| 現金股利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流率 | – | -239.2% | – | – | -91.3% | – | – | – | -99.2% | – | – | -169,528.2% |
營收拆解 2025 年度 10-K 的分部揭露 · 年增對前一年度
產品／服務2025 年度 · 6.2M
| Health Care Patient Service | 5.0M | 80.7% | -39.2% |
|---|---|---|---|
| Histology Service Fees | 1.1M | 18.1% | +1.2% |
| Medical Director Fees | 68K | 1.1% | +2.5% |
| Other Revenues | 5K | 0.1% | -34.1% |
| Department Of Defense Observational Studies | 577.00 | 0.0% | -93.3% |
| Diagnostic Research And Development | 577.00 | 0.0% | -93.3% |
| Laboratory Services 小計 | 6.2M | 100.0% | -34.1% |
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2025 | 6.2M | -34.2% | −14.9M | -242.0% | -8.66 | −9.4M |
| FY2024 | 9.4M | +269.7% | −9.0M | -96.6% | -22.50 | −7.3M |
| FY2023 | 2.5M | +52627.4% | −7.9M | -313.4% | -0.91 | −6.1M |
| FY2022 | 5K | – | −8.2M | -169,771.2% | -1.81 | −4.3M |
| FY2021 | – | – | −6.3M | –% | – | – |